

The Nomination Committee's motivated opinion regarding the proposals at the Extraordinary General Meeting on October 14, 2020

The Nomination Committee of XVIVO Perfusion AB (publ) ("the Company") hereby motivates its proposal to elect new Board members for the Company as undermentioned.

The Nomination Committee proposes that Lars Henriksson and Lena Höglund are elected new members of the Board of the Company. Dag Andersson was appointed CEO of the Company as of June 1, 2020 and now resigns from the Board. The Nomination Committee is of the opinion that the proposed Board members has the relevant competence and experience required by the Company's business, current position and future direction, and other related circumstances.

The Nomination Committee has so far during 2020 held 3 meetings where all members attended. The Nomination Committee has evaluated the Board's work inter alia, by conducting interviews on individual basis with the Boards respective members. When formulating the proposal regarding new Board members, the Nomination Committee has based its selection process on the specific requirements on the Board's combined competence, experience, and background demanded by the Company's business, current position and future direction, and other related circumstances. Furthermore, the Nomination Committee has discussed with the Board the importance of the Company conducting a planned and evolving sustainability work.

Lena Höglund has many years of solid experience in medical technology and life science. Lena currently holds a position as VP of Clinical Marketing Neuro Solutions with Elekta AB and before that she was VP of Global Marketing Portfolio Neuroscience with Elekta Instrument AB from 2016 to 2019. Lena Höglund also has years of experience with Board assignments within medicinal technology and life science companies and is a Certified board member. Lena has studied at the Stockholm School of Economics and at Management Centre Europe.

Lars Henriksson has many years of solid experience in medical technology and life science. Lars is currently a full-time Board member of AddBio AB and PositivAzimute LDA. Lars has a professional background as Executive Vice President for Dentsply, Dentsply Sirona and Astra Tech. Lars Henriksson has also worked as a dentist and holds a Master of Science in Dental Surgery from the University of Gothenburg.

In accordance with above-mentioned proposal, the Board will have 3 female Directors. The issue of equality is ever present on the agenda of the Nomination Committee and will remain prioritized.

The Nomination Committee proposes that the Board, for the time until the next General Meeting, shall comprise of six Board members and no deputies.

Furthermore, the Nomination Committee would like to communicate that the above suggested members of the Board, have been assessed as independent of the Company and the Company's major shareholders.

The Nomination Committee's assessment is that the proposed Board members satisfy the requirements placed on the Board's independence, diversity of breadth of qualifications, experience and background, and gender balance as placed on the Board by the Swedish Corporate Governance Code (the "Code"). The Nomination Committee's diversity policy consists of the Code's rule 4.1. A presentation of the proposed Board members can be found at the Company's website www.xvivoperfusion.com.

The Nomination Committee of XVIVO Perfusion AB (publ)